Market News Today — AI-Curated Stock & Crypto Headlines

Biotics AI, a winner of the TechCrunch Disrupt Battlefield 2023, has received FDA approval for its AI-powered fetal ultrasound product, enhancing detection capabilities for fetal abnormalities.

GH Research's stock rallied after the FDA lifted a hold on its experimental depression treatment, allowing the company to advance its psychedelic into Phase 3 trials, which is a positive development for other psychedelic biotechs.

Sangamo Therapeutics reported recent business highlights and third quarter 2025 financial results, including a meeting with the FDA to discuss the accelerated approval pathway for isaralgagene civaparvovec in Fabry disease, and presented positive clinical data from the registrational STAAR study.

UniQure NV shares declined after the FDA deemed the clinical data for its experimental gene-therapy for Huntington's disease as insufficient, leading to a potential delay in the drug's approval.

US stocks ended higher on Thursday, driven by strong earnings from banks such as Morgan Stanley and Goldman Sachs, as well as a boost from Taiwan-based chipmaker TSMC.

Four biotech stocks, MLYS, LYEL, NKTR, and INSM, have seen significant gains of over 50% in 2025, driven by clinical wins, FDA approvals, and M&A deals, indicating a revival of sector momentum.

FinBERT analysis of financial text showing bearish sentiment with 96.1% confidence.

The stock market is experiencing upward momentum, with the S&P 500 approaching record highs, driven by unexpected positive Q3 GDP data.

The stock of a biotech company is rising due to the departure of a polarizing FDA official, Vinay Prasad, which is seen as a positive development for the industry.

The FDA's recent rejections of experimental drugs have raised concerns among investors about the prospects of other drugs in the pipeline, potentially impacting pharmaceutical stocks.

The FDA is facing internal 'chaos' due to regulatory delays and staff shortages, which may impact the approval of rare disease treatments, posing a risk to patients with limited options.

The FDA chief has expressed concerns that the US is falling behind China in early drug development, citing three key bottlenecks in the approval process.